How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies

Blood Cancer Discov. 2021 Sep 15;2(6):562-567. doi: 10.1158/2643-3230.BCD-21-0166. eCollection 2021 Nov.


Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • COVID-19 Vaccines
  • COVID-19*
  • Hematologic Neoplasms* / therapy
  • Humans
  • Immunization, Secondary
  • SARS-CoV-2


  • COVID-19 Vaccines